Clinical study to assess the efficacy of systematic pelvic and para-aortic lymphadenectomy in patients with advanced ovarian cancer and intra-abdominal complete debulking.
Sponsor: Philipps-University Marburg
SEEK ID: https://ldh.kks-marburg.imise.uni-leipzig.de/projects/3
Funding codes:- DFG
Public web page: Not specified
NFDI4Health PIs: No PIs for this Trial Project
Trial Project start date: 12th Dec 2008
Trial Project end date: 31st Mar 2018
- : Study
- : Lymphadenectomy In Ovarian Neoplasms
- : English
- : LION
- : English
- : Clinical study to assess the efficacy of systematic pelvic and para-aortic lymphadenectomy in patients with advanced ovarian cancer and intra-abdominal complete debulking.
- : English
- : para-aortic lymphadenectomy
- : debulking
- : advanced ovarian cancer
- : Organisational
- Details about the contributing organisation(s)/institution(s)/group(s)
- : Research group
- : WA 740/4-1
- : Working Group Gynaecological Oncology (AGO) and Philipps-University Marburg/KKS
- Details about the contributing person(s)
- : Not specified
- : Not specified
- : Not specified
- Digital identifier(s)
- : Not specified
- : Not specified
- : info@kks.uni-marburg.de
- : Not specified
- Organisation(s) associated with the contributor
- : Philipps-University Marburg - KKS
- : Karl-von-Frisch-Str. 4
- : https://www.kks.uni-marburg.de
- Digital identifier(s)
- : Not specified
- : Not specified
- : NCT (ClinicalTrials.gov)
- : NCT00712218
- : Interventional
- Specification of the type of the Project
- : Parallel
- : []
- Primary health condition(s) or disease(s) considered in the Project
- : advanced ovarian cancer
- : ICD-10
- : Not specified
- Groups of diseases or conditions(*)
- : Neoplasms (II)
- : []
- : Not specified
- Administrative information about the Project
- : Request for approval submitted, approval granted
- : Completed: Recruitment, data collection, and data quality management completed normally
- : No
- : 12 December 2008
- : 31 March 2018
- : Multicentric
- : 26
- : Not specified
- : Not specified
- : Person
- Eligibility criteria for Project participants
- Eligibility criteria: Minimum age
- : 18
- : Years
- Eligibility criteria: Maximum age
- : 75
- : Years
- : Female
- : see protocol
- : see protocol
- Population of the Project(*)
- : National
- : Germany
- : nationwide
- Interventions of the Project
- : systematic pelvic and para-aortic lymphadenectomy (LNE) during cytoreductive surgery according to AGO recommendations
- : Procedure/Surgery
- : Not specified
- : Experimental intervention
- Exposures of the Project
- : Not specified
- : Not specified
- : Not specified
- : Not specified
- Outcome measures in the Project
- : Overall survival
- : Not specified
- : Primary
- : 6 years
- : Not specified
- : []
- Data sharing strategy of the Project(*)
- : Undecided, it is not yet known if data will be made available
- : []
- : Not specified
- : Not specified
- : Not specified
- : Not specified
- : Not specified
- : Not specified
- : Not specified
- Non-interventional aspects of the Project
- : []
- Target follow-up duration of the Project
- : Not specified
- : Not specified
- : Not specified
- : []
- : Not specified
- Interventional aspects of the Project
- : Not applicable
- Masking of intervention(s) assignment
- : false
- : []
- : Not specified
- : Randomized
- : Not applicable
Related items
Trial Projects:
- Phosphodiesterase-5 inhibition in patients with heart failure with preserved ejection fraction and combined post- and pre-capillary pulmonary hypertension (PASSION)
- Lymphadenectomy in Ovarian Neoplasms (LION)
- Efficacy and safety of adjuvant immunoadsorption in pemphigus vulgaris and pemphigus foliaceus (IA-pem)
- A randomized multicenter study to compare the efficacy of additional tumor debulking surgery versus chemotherapy alone for recurrent platinum-sensitive ovarian cancer
- Efficacy and Safety of Pegylated-Proline-Interferon Alpha 2b (AOP2014) in Maintaining Deep Molecular Remissions in Patients with Chronic Myeloid Leukemia (CML) who Discontinue ABL-Kinase Inhibitor Therapy
- A randomized, placebo-controlled, double-blind, multi-centre trial to assess the disease-modifying potential of transdermal nicotine in early Parkinson's disease in Germany and the USA
Institutions: Philipps-University Marburg, Coordinating Center for Clinical Trials

Trial Projects:
- Phosphodiesterase-5 inhibition in patients with heart failure with preserved ejection fraction and combined post- and pre-capillary pulmonary hypertension (PASSION)
- Lymphadenectomy in Ovarian Neoplasms (LION)
- Efficacy and safety of adjuvant immunoadsorption in pemphigus vulgaris and pemphigus foliaceus (IA-pem)
- A randomized, placebo-controlled, double-blind, multi-centre trial to assess the disease-modifying potential of transdermal nicotine in early Parkinson's disease in Germany and the USA
- A randomized multicenter study to compare the efficacy of additional tumor debulking surgery versus chemotherapy alone for recurrent platinum-sensitive ovarian cancer
- Efficacy and Safety of Pegylated-Proline-Interferon Alpha 2b (AOP2014) in Maintaining Deep Molecular Remissions in Patients with Chronic Myeloid Leukemia (CML) who Discontinue ABL-Kinase Inhibitor Therapy
Web page: Not specified
Abstract (Expand)
Authors: P. Harter, J. Sehouli, D. Lorusso, A. Reuss, I. Vergote, C. Marth, J. W. Kim, F. Raspagliesi, B. Lampe, G. Aletti, W. Meier, D. Cibula, A. Mustea, S. Mahner, I. B. Runnebaum, B. Schmalfeldt, A. Burges, R. Kimmig, G. Scambia, S. Greggi, F. Hilpert, A. Hasenburg, P. Hillemanns, G. Giorda, I. von Leffern, C. Schade-Brittinger, U. Wagner, A. du Bois
Date Published: 28th Feb 2019
Publication Type: Journal
PubMed ID: 30811909
Citation: N Engl J Med. 2019 Feb 28;380(9):822-832. doi: 10.1056/NEJMoa1808424.
Creator: Gerrit zur Hausen
Submitter: Gerrit zur Hausen